PatentAug 5, 2026, 08:33 AM
Vivos Therapeutics Secures New Patent for OSA Treatment Devices
AI Summary
Vivos Therapeutics announced the issuance of US Patent No. 12,697,190, a continuation of a previously issued patent, which broadens the intellectual property protection for its Vivos CARE oral medical devices. These devices have received two unprecedented FDA 510K clearances for treating severe obstructive sleep apnea (OSA) in adults and moderate-to-severe OSA in children. The company believes this new patent strengthens its industry position and technological advantages, especially given the documented health risks and recalls associated with CPAP devices.
Key Highlights
- US Patent No. 12,697,190, "Vibrational Oral Appliance with Mandibular Advancements," was issued.
- This new patent is a continuation of US Patent No. 12,048,608, issued July 30, 2024.
- The patents broaden protection for Vivos CARE devices, which have two FDA 510K clearances.
- Vivos CARE devices treat severe OSA in adults and moderate-to-severe OSA in children (ages 6-17).
- Studies show approximately 80% of patients achieve significant reduction or resolution of OSA symptoms.
- Over 5 million CPAP units have been recalled since 2021.
- More than 1 billion people globally and up to 90 million Americans suffer from sleep apnea.
Price Impact
More from VVOS